76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

Autor: Justeau, G., Pérol, M., Valette, C. Audigier, Debieuvre, D., Quantin, X., Lena, H., Macouillard, P., Bosquet, L., Schoemaker, M.J., Mella, M., Correia, B., Rault, C., Daumont, M.J., Penrod, J., Chouaid, C.

Publikováno v: In Immuno-Oncology and Technology December 2023 20 Supplement

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

Autor: H. Borghaei, D. Balli, L. Paz-Ares, M. Reck, S.S. Ramalingam, J.R. Brahmer, T-E. Ciuleanu, A. Pluzanski, J-S. Lee, J. Gainor, M. Schenker, A. Schoenfeld, R. Bernabe Caro, N. Ready, K.H. Lee, B. Zurawski, C. Audigier-Valette, V. Baxi, W. Geese, K.J. O’Byrne

Publikováno v: Journal of Thoracic Oncology. 18:S64-S65

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::721c6319fc853766964d5fc594abb609
https://doi.org/10.1016/s1556-0864(23)00295-2

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Autor: O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I. Monnet, G. Jeannin, J. Mazières, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V. Westeel, P. Brun, A. Langlais, F. Morin, P.J. Souquet, N. Girard

Publikováno v: ESMO Open
ESMO Open, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩
ESMO Open, European Society for Medical Oncology, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩

Background Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). Materials a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca79719ac7e0d0d9f96b94dc3cb9c4f
https://hal.sorbonne-universite.fr/hal-03512207/document